Galectin approach to lower covid transmission - Drug Development for clinical use

Alben Sigamani, Kevin H Mayo, Hana Chen-Walden, Surender Reddy, David Platt
doi: https://doi.org/10.1101/2022.11.09.22282151

Article Information

doi 
https://doi.org/10.1101/2022.11.09.22282151
History 
  • November 18, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Alben Sigamani1,*,
  2. Kevin H Mayo2,
  3. Hana Chen-Walden3,
  4. Surender Reddy4 and
  5. David Platt3
  1. 1Carmel Research Consultancy Pvt. Ltd., Bengaluru, Karnataka 560025, India
  2. 2Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 6-155 Jackson Hall, 321 Church Street, Minneapolis, MN 55455, USA
  3. 3Pharmalectin India Pvt. Ltd., Rangareddy, Telangana 500039, India
  4. 4Department of Pulmonology, ESIC Medical college and Hospital, Sanath Nagar, Hyderabad, Telangana 500038, India
  1. ↵*Corresponding author:
    Dr. Alben Sigamani,Carmel Research Consultancy Pvt. Ltd., Bengaluru, Karnataka 560025, India, Phone: +918884431444, Email: dralbens{at}myrescon.com
Back to top
Posted November 18, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Galectin approach to lower covid transmission - Drug Development for clinical use
Alben Sigamani, Kevin H Mayo, Hana Chen-Walden, Surender Reddy, David Platt
medRxiv 2022.11.09.22282151; doi: https://doi.org/10.1101/2022.11.09.22282151
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area